The Wingspan® stent system was approved as a rescue device for angioplasty of intracranial atherosclerotic disease (ICAD) in 2012. We conducted the government recommended Japanese Post-Market Surveillance of Percutaneous Transluminal Angioplasty and Wingspan Stenting for Intracranial Atherosclerotic Disease (WICAD) to monitor Wingspan safety and performance. In this open-label, single-arm study at 76 centers in Japan, ICAD subjects were treated with the Wingspan stent between 2014 and 2016. Efficacy endpoints were successful stent deployment and technical success, defined as stenosis improvement to <50%. Safety endpoints were ischemic stroke, modified Rankin Scale (mRS) and National Institutes of Health Stroke Scale (NIHSS) scores, adverse events (AEs) and mortality. Subjects were considered treated outside of current recommendations if not already receiving anti-thrombotics or if PTAS occurred within 7 days of onset. The Safety Cohort included 305 subjects (mean age 68.7+9.6; 83.3% male). Four subjects were removed due to being out of contract. Therefore, 301 subjects were included (mean age 68.7±9.7; 84.1% male). Successful stent placement was 96.7%. Technical success was observed in 86.8% of lesions. At 1 year, the rate of restenosis was 15.7%, ischemic stroke was 3.9% and any stroke was 7.9%. Functionally independent outcome (mRS 0-2) was 88.9% and mortality 3.0%. Significantly more serious adverse events (SAEs) occurred in subjects treated outside of current recommendations (17.9%) vs. subjects treated per current recommendations (8.8%) (p=0.045). Endovascular treatment using the Wingspan stent for ICAD is safe and effective in the Japanese population.